建立和临床应用一种将随机度转换为稳定状态最低度的方法
Jiezheng Dong1, Lingshan Qiu1, Zhonglin Tan1
1Department of Psychiatry, The Seventh People's Hospital of Hangzhou (Affiliated Mental Health Center, Zhejiang University School of Medicine), Hangzhou, Zhejiang Province, China.
Asian journal of psychiatry
|February 22, 2026
概括
一个新的药理动力学模型准确地将随机氨酸 (QTP) 和N-脱甲基氨酸 (N-QTP) 水平转换为稳定状态的最低度. 这种方法增强了治疗药物监测 (TDM) 用于在精神分裂症和双相情感障碍的个性化氨酸治疗.
科学领域:
- 药理动力学和药物新陈代谢
- 临床药理学 临床药理学
- 精神病学治疗学 精神病学治疗学
背景情况:
- 治疗药物监测 (TDM) 氨酸 (QTP) 对于管理精神分裂症和双相情感障碍至关重要.
- 解释QTP及其活性代谢物N-desmethylquetiapine (N-QTP) 的非标准时间样本是一个临床挑战.
- 准确的TDM依赖于可靠的稳定状态最低度测量.
研究的目的:
- 开发和验证一种基于药理动力学模型的方法,用于将随机QTP和N-QTP度转换为稳定状态低谷水平.
- 为了解决在TDM中解释非标准血液样本的临床需求.
- 为了提高提氨酸TDM的准确性和适用性.
主要方法:
- 系统性文献审查以确认核心药理动力学参数 (QTP半衰期:7小时;N-QTP半衰期:12小时).
- 基于第一阶动力衰变的特定相位转换公式的推导,使用剂量后14小时作为标准低谷时间.
- 使用80名精神分裂症患者队列的验证,将估计的最低度与同时测量的黄金标准最低度进行比较.
主要成果:
- 用于剂后1-48小时的时间点生成的转换系数.
- 在QTP (r=0.89),N-QTP (r=0.91) 和总度 (r=0.92) 的估计和测量最低度之间显示出强烈的一致性.
- 实现了高精度,QTP的平均相对误差低于10.1%,N-QTP为7.8%,总度为9.2%,最佳性能在6-10小时之间.
结论:
- 开发的转换方法经过了严格的验证,并显示了对奎平临床TDM的强大的准确性.
- 为解释非标准低谷样本提供了一个实用的工具 (查找表).
- 通过在标准采样不可行时实现可靠的TDM,促进个性化的奎蒂阿平治疗.
更多相关视频
相关概念视频
Dosage Regimen: Multiple Oral Dosage
295
Understanding how a drug's concentration fluctuates within the body over time is crucial in pharmacokinetics, particularly with multiple oral doses. A graphical representation of multiple oral dosages provides insight into these dynamics. Typical accumulation curves of a drug's concentration in the body reveal a sawtooth pattern, indicating periodic peaks and troughs correlating with each dose administration and the drug's subsequent elimination.The plasma concentration at any time during an...
295
Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance
729
The elimination half-life and drug clearance of drugs following nonlinear kinetics can vary with dosage. The Michaelis-Menten parameters and drug concentration influence these factors. As the dose increases, the elimination half-life tends to lengthen, resulting in a reduction in clearance and a disproportionately larger area under the curve. The total clearance can be derived from the Michaelis-Menten equation for drugs following a one-compartment model.
A study on guinea pigs examined the...
A study on guinea pigs examined the...
729
Pharmacokinetic–Pharmacodynamic Relationship: Problems
33
The empirical approach to drug therapy optimization relies on correlating pharmacological response with administered dosage. Such an approach can be costly, time-consuming, and often yields poor correlation due to variables like formulation factors and drug elimination characteristics. A more precise approach correlates response with plasma drug concentration or the amount of drug in the body, rather than dosage. This is achieved through pharmacokinetic-pharmacodynamic (PK/PD) modeling, which...
33
IV Infusion to Oral Dosing: Conversion Methods
47
The development of extended-release formulations has facilitated the transition from intravenous to oral medication, offering a more convenient and patient-friendly approach to drug administration. This transition, however, requires careful management to ensure that therapeutic drug levels are maintained, preserving efficacy and avoiding adverse effects. Understanding pharmacokinetic principles and dosage calculations is critical during this process.Pharmacokinetics of the...
47
Measurement of Bioavailability: Pharmacokinetic Methods
343
Pharmacokinetics is a vital branch of pharmacology that examines how drugs are absorbed, distributed, metabolized, and excreted by the body. Two key methodologies in pharmacokinetics are plasma drug concentration studies and urinary drug excretion analyses, both of which provide critical insights into a drug's therapeutic efficacy and bioavailability.Plasma Drug Concentration-Time StudiesPlasma drug concentration-time studies involve analyzing blood samples at specific intervals to quantify...
343
Dosage Regimens: Partial Pharmacokinetic Parameters
225
It is not uncommon for complete drug pharmacokinetic profiles to remain elusive in pharmacokinetics. This necessitates certain educated assumptions by pharmacokineticists to determine appropriate dosage regimens without comprehensive pharmacokinetic data from animal or human studies. One prevalent assumption is setting the bioavailability factor, denoted as F, to 1 or 100%. This assumption caters to the scenario where a drug doesn't achieve full systemic absorption, resulting in the patient...
225


